Seeking Alpha

Oppenheimer reiterates its "Outperform" rating on Gilead (GILD -0.2%), saying that the company...

Oppenheimer reiterates its "Outperform" rating on Gilead (GILD -0.2%), saying that the company has a number of under-appreciated opportunities related to its HIV combination treatments. Oppenheimer therefore reckons Gilead will generate more money from those medicines than expected.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs